Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effective treatment of small murine hepatocellular carcinoma by dendritic cells
Autore:
Lee, WC; Wang, HC; Jeng, LB; Chang, YJ; Lia, CR; Huang, PF; Chen, MF; Qian, SG; Lu, LN;
Indirizzi:
Chang Gung Mem Hosp, Dept Gen Surg, Immunol Lab, Taoyuan Hsien, Taiwan Chang Gung Mem Hosp Taoyuan Hsien Taiwan nol Lab, Taoyuan Hsien, Taiwan Chang Gung Mem Hosp, Dept Urol, Immunol Lab, Taoyuan Hsien, Taiwan Chang Gung Mem Hosp Taoyuan Hsien Taiwan nol Lab, Taoyuan Hsien, Taiwan Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA Univ Pittsburgh Pittsburgh PA USA Transplantat Inst, Pittsburgh, PA USA
Titolo Testata:
HEPATOLOGY
fascicolo: 5, volume: 34, anno: 2001,
pagine: 896 - 905
SICI:
0270-9139(200111)34:5<896:ETOSMH>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR; TGF-BETA; CANCER-IMMUNOTHERAPY; IMMUNE-RESPONSES; NATURAL-HISTORY; FAS LIGAND; TUMORS; MELANOMA; IMMUNOSUPPRESSION; INTERLEUKIN-10;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Lee, WC Chang Gung Mem Hosp, Dept Surg, 5 Fu Hsing St, Taoyuan Hsien, Taiwan Chang Gung Mem Hosp 5 Fu Hsing St Taoyuan Hsien Taiwan n, Taiwan
Citazione:
W.C. Lee et al., "Effective treatment of small murine hepatocellular carcinoma by dendritic cells", HEPATOLOGY, 34(5), 2001, pp. 896-905

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy with a poor prognosis. This investigation examined whether dendritic cell-based immunotherapy can treat murine HCC effectively. Bone marrow-derived dendritic cells were propagated from C57BL/10J mice in GM-CSF (4 ng/mL) and interleukin (IL)-4 (1,000 mu /mL). The dendritic cells were pulsed with a Hepal-6 lysate overnight and employed to treat murine HCC. For in vivo study, HCC was created by inoculation of hepal-6, 5 x 10(5) cells, in the flank of C57BL/10J mice. HCC were categorized into small (3 x 3-mm) and large (5 x 5-mm) tumors. TheseHCC were treated by dendritic cells intravenously, twice at weekly intervals. The results revealed that lymphocytes could be gathered around small HCC after administration of Hepal-6 lysate-pulsed dendritic cells. Seven of 12 (58.3%) small HCC could be eradicated completely by dendritic cell-based immunotherapy, and 33.3% of the small tumors responded to immunotherapy partially which were held in a stable condition for 34.0 +/- 7.4 days before the tumors regrew. For large HCC, lymphocytes did not gather around the tumors, and the tumors cannot be eradicated effectively by dendritic cells. However, dendritic cell-based immunotherapy could slow down the growth rate oflarge tumors (116.2 +/- 91.4 mm(3) vs. 234.0 +/- 149.1 mm(3) of the control on day 7, P = .043; and 280.3 +/- 224.7 mm(3) vs. 870.0 +/- 418.9 MITI 3 of the control on day 17, P < .001). Conclusively, dendritic cells pulsed with a Hepal-6 lysate can be employed to treat small HCC in vivo effectively. However, the efficacy of dendritic cell-based immunotherapy decreases while tumors grow.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 08:07:35